Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: January 28, 2023

Details for Patent: 8,338,489

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 8,338,489
Title:Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract: The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s): Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Beno t (Bordeaux, FR)
Assignee: Universite Victor Segalen--Bordeaux 2 (Bordeaux Cedex, FR)
Application Number:12/599,266
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,338,489
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,338,489

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD TO TREAT HEMANGIOMA. See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,338,489

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07291273Oct 19, 2007
PCT Information
PCT FiledOctober 16, 2008PCT Application Number:PCT/IB2008/002746
PCT Publication Date:April 23, 2009PCT Publication Number: WO2009/050567

International Family Members for US Patent 8,338,489

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 068927 See Plans and Pricing
Austria 512661 See Plans and Pricing
Australia 2008313405 See Plans and Pricing
Brazil PI0816536 See Plans and Pricing
Canada 2701953 See Plans and Pricing
Chile 2008003083 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.